- Home
- ATAI vs SYRE Comparison
ATAI vs SYRE Comparison
Compare ATAI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- SYRE
- Stock Information
- Founded
- ATAI 2018
- SYRE 2013
- Country
- ATAI Netherlands
- SYRE United States
- Employees
- ATAI N/A
- SYRE N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- SYRE Health Care
- Exchange
- ATAI Nasdaq
- SYRE Nasdaq
- Market Cap
- ATAI 1.1B
- SYRE 1.1B
- IPO Year
- ATAI 2021
- SYRE 2016
- Fundamental
- Price
- ATAI $5.84
- SYRE $24.46
- Analyst Decision
- ATAI Strong Buy
- SYRE Strong Buy
- Analyst Count
- ATAI 5
- SYRE 5
- Target Price
- ATAI $14.00
- SYRE $55.75
- AVG Volume (30 Days)
- ATAI 7.0M
- SYRE 1.4M
- Earning Date
- ATAI 11-14-2025
- SYRE 11-06-2025
- Dividend Yield
- ATAI N/A
- SYRE N/A
- EPS Growth
- ATAI N/A
- SYRE N/A
- EPS
- ATAI N/A
- SYRE N/A
- Revenue
- ATAI $2,309,000.00
- SYRE N/A
- Revenue This Year
- ATAI $736.04
- SYRE N/A
- Revenue Next Year
- ATAI N/A
- SYRE N/A
- P/E Ratio
- ATAI N/A
- SYRE N/A
- Revenue Growth
- ATAI 510.85
- SYRE N/A
- 52 Week Low
- ATAI $1.04
- SYRE $10.91
- 52 Week High
- ATAI $6.75
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- ATAI 54.11
- SYRE 69.54
- Support Level
- ATAI $5.50
- SYRE $23.52
- Resistance Level
- ATAI $6.23
- SYRE $25.06
- Average True Range (ATR)
- ATAI 0.47
- SYRE 1.31
- MACD
- ATAI -0.05
- SYRE 0.13
- Stochastic Oscillator
- ATAI 36.10
- SYRE 90.62
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.